# OnCo record relativity-047 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/relativity-047/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "relativity-047", "NCT03470922" ;
  schema:name "RELATIVITY-047"@en ;
  schema:description "Proved that adding a LAG-3 blocker to PD-1 blockade delays progression, with far less toxicity than the ipilimumab combination."@en ;
  schema:url <https://onco.cc/trials/relativity-047/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03470922>, <https://ascopubs.org/doi/10.1200/JCO.24.01124>, <https://www.ejcancer.com/article/S0959-8049(25)00329-6/fulltext> ;
  onco:status "positive" ;
  onco:phase "2/3" ;
  schema:startDate "2018-04-11" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:trials <https://onco.cc/trials/checkmate-067/> ;
  onco:people <https://onco.cc/people/hussein-tawbi/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-relativity-047-nejm-2022/>, <https://onco.cc/key-papers/paper-relativity-047-nejm-evid-2023-update/> .